SpyGlass Pharma (SGP) Non-Current Assets (2024 - 2026)
SpyGlass Pharma (SGP) posted quarterly Non-Current Assets of $7.1 million for Q4 2025, up 20.06% year-over-year from $5.9 million in Q4 2024, and up 20.06% quarter-over-quarter from $5.9 million in Q4 2024.
SpyGlass Pharma (SGP) Non-Current Assets (2024 - 2026) Analysis & Trends
SpyGlass Pharma (SGP) has reported Non-Current Assets for 2 consecutive years, with $7.1 million the latest figure, recorded in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | SpyGlass Pharma | 876.29 Mn | 876.29 Mn | - | 6.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.97 Mn |
| Dec 31, 2025 | 7.10 Mn |
| Dec 31, 2024 | 5.91 Mn |